The winner and loser of cancer treatmen
۔
Taiwan biotechnology investors' understanding of the American Society of Clinical Oncology (ASCO) should start from March 2016 when Hao Ding said that he would go to ASCO to publish a paper. At that time, Hao Ding was in the storm period after the failure of the new drug to solve the blindness. In order to explain the ASCO's oral report to the counter buying center, he also announced that the stock price was suspended. The news headline stated that "Hao Ding's blind paper was confirmed by ASC O". "Hao Ding was invited by ASCO to go straight to the daily limit," and these "affirmative" words seem to imply that investors are "safe". The next day's stock price opening even reversed the previous decline in blindness.
Later, on June 5, 2016, after Hao Ding officially released the data in ASCO, the investors saw the details of the data of the real clinical failure for the first time, and the disillusionment caused the stock price to fall all the way. The pain caused by the Hao Ding incident three years ago has become a history in the history of biotechnology investment in Taiwan, but ASCO continues to exert influence on the stage of world oncology. From the winners of ASCO, we can also see the new direction of research and development. .
Information platform exchange cancer treatment new research
ASCO is a leading global cancer cancer research organization with a team of professional clinicians and cancer researchers. The annual conference is attended by more than 30,000 people from 100 countries and more than 4,000 scientists. ASCO is an important medical information exchange platform and the main arena of companies or institutions around the world for cancer research, in an attempt to attract international attention. Look and look for opportunities for business collaboration.
From the past history, the publication of clinical data by ASCO does have an impact on the company's stock price. The industry has given the name "ASCO Effect" (ASCO effect). Before and after the annual meeting, from the companies that publish clinical data, the professional media will select winners and losers. The stock prices of these companies will often go to the world. What is important is that from the publication of these winners, it can be seen that the global anti-cancer drugs R&D trends.
At the ASCO annual meeting in 2016, 2017 and 2018, CAR-T cell immunotherapy, immunological checkpoint inhibitors (such as PD-1 inhibitors), antibody drugs, and PARP inhibitors are all popular.
In 2017, it is a pity that the “IDO inhibitors”, which have always been favored in the field of immunotherapy, have been abandoned by big manufacturers because of poor clinical data. In addition, the worst of the year was Puma's new breast cancer drug Neratinib, which was questioned because of the side effects of severe diarrhea; although the company tried to prove that the side effects could be controlled by the anti-diarrheal drug Loperamide, the market did not pay the bill, causing the stock price to plummet 3 Cheng, the market value depreciated by 2 billion US dollars.
New drug 槌 槌 company's share price collapsed
In contrast, what cancer can kill LOXO's Larotrectinib, in lung cancer, stomach cancer, bladder cancer, kidney cancer, colon cancer, pancreatic cancer, etc., as well as rare cancers such as salivary gland cancer, juvenile breast cancer, known as infants In soft tissue cancer of fibrosarcoma in children, the objective response rate of tumors in 17 cancers is as high as 76%. The ASCO conference in 2017 is so popular that the stock price has risen by 50%. A few months after ASCO published its eye-catching data, Bayer Pharmaceuticals partnered with LOXO to develop Larotrectinib for $850 million. In 2019, the company also attracted LOXO for $8 billion, which is the story of ASCO's super winner.
The big loser in 2018 was the Roche Pharmaceuticals. The company's new breast cancer drug Taselisib combined with standard hormonal therapy in Phase 3 clinical trials has no worsening survival (PFS), which is only 2 months longer than hormone monotherapy, and there are various side effects that exceed 3 levels of severity, leading to Roche's decision. Suspend development. In addition, Roche's other immunotherapeutic drug, Tecentriq, for the treatment of squamous cell lung cancer was originally expected to have a chance to defeat Merck's Keytruda, and the results were not as expected. The final market value evaporated by $17.4 billion.
As for the big winner in 2018, ASCO's Merck PD-1 checkpoint inhibitor Keytruda (immunotherapy) came to the forefront of the king. The drug announced two first-line treatments for non-small cell lung cancer, with an overall survival of up to 20 months, 12 months higher than chemotherapy, and far worse than Roche's Tecentriq.
Good clinical data is definitely a plus for sales, which can be seen in the 18-year sales figures, with the Merck PD-1 inhibitor Keytruda reaching $7.2 billion and the Squibb PD-1 inhibitor Opdivo being $6.7 billion. Sales of Roche's PD-L1 inhibitor Tecentriq are only $770 million.
Time is coming to 2019, it is worthy of the attention of Taiwan's new drug companies. This year's focus is no longer an objective relief of the tumor (including the inability to detect complete remission of the tumor and partial relief of tumor reduction by 30%), but the quality of life of the patient. The absence of worsening survival and the overall survival of life expectancy.
Immunotherapy has been in focus for 2 consecutive years۔
Obviously, this year's big winner is Merck's immunotherapy star Keytruda. Since receiving the first drug treatment for advanced melanoma in 2014, he has now obtained 19 indications for indications. Most of the drug certificates obtained by Keytruda were approved by the FDA (US Food and Drug Administration) for the tumor remission rate. Now the FDA requires more patient survival data, so this time ASCO, Merck published advanced non-small cells. Clinical data on lung cancer is focused on survival data. The results showed that Keytruda's 5-year average survival rate was as high as 18%, and the 5-year average survival rate before the emergence of immunotherapy was only 5.5%, which is indeed an amazing breakthrough.
Another highlight of ASCO in 2019 is the new development of liquid slicing that is closely related to precision medicine. Everyone knows that early detection and early treatment of cancer is critical to the outcome of the prognosis, and liquid sectioning is one of the emerging methods for detecting early cancer. Gene sequencing leader Grail, a subsidiary of Illumina, also includes the well-known Amazon, Microsoft, Squibb, Merck, Johnson & Johnson and Tencent, and finally released the company's liquid slicing technology platform transcript this year.
This time, Grail's technology platform can use blood to detect 12 kinds of cancers at an early stage, and can understand where the cancer tumors occur before they spread. In addition, the probability of false positives (no cancer is said to have cancer) is only 1%. Among them, detection sensitivity: anorectal cancer (79%), colorectal cancer (74%), esophageal cancer (76%), gastric cancer (78%), head and neck cancer (86%), hormone receptor-negative breast cancer (64%) ), liver (68%), lung cancer (59%), ovary (67%) and pancreas (78%), as well as multiple myeloma (71%), lymphoma (70%).
When Taiwanese investors met ASCO because of the Haoding incident, and even naively thought they could participate in ASCO, it seems that they are not far from getting the drug certificate. However, it turns out that ASCO's publication is different from winners and losers. In the past three years, Taiwan’s investors have become smarter. To see the real clinical data, it’s just a matter of seeing it. Therefore, going to the ASCO report does not help the stock price. This year, Taiwan has only Guoding, Polaris and Taizong. And Zhiqing foreign partners participated in the ASCO publication.
In fact, ASCO did not have a particularly amazing new technology platform in 2019, but in recent years, because cell therapy and gene therapy are rapidly developing, former US FDA director Scott Gottlieb also predicts that 10-20 cells will be passed every year in 2025. And gene therapy products are on the market, so perhaps ASCO in 2020 can expect cell and gene therapy to shine at the venue.
Taiwan biotechnology investors' understanding of the American Society of Clinical Oncology (ASCO) should start from March 2016 when Hao Ding said that he would go to ASCO to publish a paper. At that time, Hao Ding was in the storm period after the failure of the new drug to solve the blindness. In order to explain the ASCO's oral report to the counter buying center, he also announced that the stock price was suspended. The news headline stated that "Hao Ding's blind paper was confirmed by ASC O". "Hao Ding was invited by ASCO to go straight to the daily limit," and these "affirmative" words seem to imply that investors are "safe". The next day's stock price opening even reversed the previous decline in blindness.
Later, on June 5, 2016, after Hao Ding officially released the data in ASCO, the investors saw the details of the data of the real clinical failure for the first time, and the disillusionment caused the stock price to fall all the way. The pain caused by the Hao Ding incident three years ago has become a history in the history of biotechnology investment in Taiwan, but ASCO continues to exert influence on the stage of world oncology. From the winners of ASCO, we can also see the new direction of research and development. .
Information platform exchange cancer treatment new research
ASCO is a leading global cancer cancer research organization with a team of professional clinicians and cancer researchers. The annual conference is attended by more than 30,000 people from 100 countries and more than 4,000 scientists. ASCO is an important medical information exchange platform and the main arena of companies or institutions around the world for cancer research, in an attempt to attract international attention. Look and look for opportunities for business collaboration.
From the past history, the publication of clinical data by ASCO does have an impact on the company's stock price. The industry has given the name "ASCO Effect" (ASCO effect). Before and after the annual meeting, from the companies that publish clinical data, the professional media will select winners and losers. The stock prices of these companies will often go to the world. What is important is that from the publication of these winners, it can be seen that the global anti-cancer drugs R&D trends.
At the ASCO annual meeting in 2016, 2017 and 2018, CAR-T cell immunotherapy, immunological checkpoint inhibitors (such as PD-1 inhibitors), antibody drugs, and PARP inhibitors are all popular.
In 2017, it is a pity that the “IDO inhibitors”, which have always been favored in the field of immunotherapy, have been abandoned by big manufacturers because of poor clinical data. In addition, the worst of the year was Puma's new breast cancer drug Neratinib, which was questioned because of the side effects of severe diarrhea; although the company tried to prove that the side effects could be controlled by the anti-diarrheal drug Loperamide, the market did not pay the bill, causing the stock price to plummet 3 Cheng, the market value depreciated by 2 billion US dollars.
New drug 槌 槌 company's share price collapsed
In contrast, what cancer can kill LOXO's Larotrectinib, in lung cancer, stomach cancer, bladder cancer, kidney cancer, colon cancer, pancreatic cancer, etc., as well as rare cancers such as salivary gland cancer, juvenile breast cancer, known as infants In soft tissue cancer of fibrosarcoma in children, the objective response rate of tumors in 17 cancers is as high as 76%. The ASCO conference in 2017 is so popular that the stock price has risen by 50%. A few months after ASCO published its eye-catching data, Bayer Pharmaceuticals partnered with LOXO to develop Larotrectinib for $850 million. In 2019, the company also attracted LOXO for $8 billion, which is the story of ASCO's super winner.
The big loser in 2018 was the Roche Pharmaceuticals. The company's new breast cancer drug Taselisib combined with standard hormonal therapy in Phase 3 clinical trials has no worsening survival (PFS), which is only 2 months longer than hormone monotherapy, and there are various side effects that exceed 3 levels of severity, leading to Roche's decision. Suspend development. In addition, Roche's other immunotherapeutic drug, Tecentriq, for the treatment of squamous cell lung cancer was originally expected to have a chance to defeat Merck's Keytruda, and the results were not as expected. The final market value evaporated by $17.4 billion.
As for the big winner in 2018, ASCO's Merck PD-1 checkpoint inhibitor Keytruda (immunotherapy) came to the forefront of the king. The drug announced two first-line treatments for non-small cell lung cancer, with an overall survival of up to 20 months, 12 months higher than chemotherapy, and far worse than Roche's Tecentriq.
Good clinical data is definitely a plus for sales, which can be seen in the 18-year sales figures, with the Merck PD-1 inhibitor Keytruda reaching $7.2 billion and the Squibb PD-1 inhibitor Opdivo being $6.7 billion. Sales of Roche's PD-L1 inhibitor Tecentriq are only $770 million.
Time is coming to 2019, it is worthy of the attention of Taiwan's new drug companies. This year's focus is no longer an objective relief of the tumor (including the inability to detect complete remission of the tumor and partial relief of tumor reduction by 30%), but the quality of life of the patient. The absence of worsening survival and the overall survival of life expectancy.
Immunotherapy has been in focus for 2 consecutive years۔
Obviously, this year's big winner is Merck's immunotherapy star Keytruda. Since receiving the first drug treatment for advanced melanoma in 2014, he has now obtained 19 indications for indications. Most of the drug certificates obtained by Keytruda were approved by the FDA (US Food and Drug Administration) for the tumor remission rate. Now the FDA requires more patient survival data, so this time ASCO, Merck published advanced non-small cells. Clinical data on lung cancer is focused on survival data. The results showed that Keytruda's 5-year average survival rate was as high as 18%, and the 5-year average survival rate before the emergence of immunotherapy was only 5.5%, which is indeed an amazing breakthrough.
Another highlight of ASCO in 2019 is the new development of liquid slicing that is closely related to precision medicine. Everyone knows that early detection and early treatment of cancer is critical to the outcome of the prognosis, and liquid sectioning is one of the emerging methods for detecting early cancer. Gene sequencing leader Grail, a subsidiary of Illumina, also includes the well-known Amazon, Microsoft, Squibb, Merck, Johnson & Johnson and Tencent, and finally released the company's liquid slicing technology platform transcript this year.
This time, Grail's technology platform can use blood to detect 12 kinds of cancers at an early stage, and can understand where the cancer tumors occur before they spread. In addition, the probability of false positives (no cancer is said to have cancer) is only 1%. Among them, detection sensitivity: anorectal cancer (79%), colorectal cancer (74%), esophageal cancer (76%), gastric cancer (78%), head and neck cancer (86%), hormone receptor-negative breast cancer (64%) ), liver (68%), lung cancer (59%), ovary (67%) and pancreas (78%), as well as multiple myeloma (71%), lymphoma (70%).
When Taiwanese investors met ASCO because of the Haoding incident, and even naively thought they could participate in ASCO, it seems that they are not far from getting the drug certificate. However, it turns out that ASCO's publication is different from winners and losers. In the past three years, Taiwan’s investors have become smarter. To see the real clinical data, it’s just a matter of seeing it. Therefore, going to the ASCO report does not help the stock price. This year, Taiwan has only Guoding, Polaris and Taizong. And Zhiqing foreign partners participated in the ASCO publication.
In fact, ASCO did not have a particularly amazing new technology platform in 2019, but in recent years, because cell therapy and gene therapy are rapidly developing, former US FDA director Scott Gottlieb also predicts that 10-20 cells will be passed every year in 2025. And gene therapy products are on the market, so perhaps ASCO in 2020 can expect cell and gene therapy to shine at the venue.
The winner and loser of cancer treatmen
Reviewed by Health Tips
on
July 01, 2019
Rating:
Reviewed by Health Tips
on
July 01, 2019
Rating:
No comments: